Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NISxWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGdI1KSzVyPUCuNFAxODVzMzFOwG0> M2HadHNCVkeHUh?=
NCI-H1703 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMECwPVAzKM7:TR?= NInjfIZUSU6JRWK=
KASUMI-1 NHnPXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrnTWM2OD1yLkCwOlgzKM7:TR?= MlHEV2FPT0WU
CGTH-W-1 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEC3NlIh|ryP MYPTRW5ITVJ?
A204 NECyflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HmXmlEPTB;MD6wNFk6OiEQvF2= M3vld3NCVkeHUh?=
HOP-62 M1PxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC3XmhMUUN3ME2wMlExQDN4IN88US=> MnLmV2FPT0WU
H-EMC-SS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDITJdKSzVyPUCuNVExODVizszN NXrtbINSW0GQR1XS
KU812 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3R2lEPTB;MD6xOlU4PyEQvF2= MYTTRW5ITVJ?
EM-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMU[4NVYh|ryP NWnJbpdWW0GQR1XS
LAMA-84 NHTITWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf1eYRzUUN3ME2wMlE4PjZ3IN88US=> NX;XSIh[W0GQR1XS
JAR M1jDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6bmZOUUN3ME2wMlI{QTh7IN88US=> MlvXV2FPT0WU
G-361 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XMdGlEPTB;MD6zNlMzPSEQvF2= MWHTRW5ITVJ?
KG-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTuOnRKSzVyPUCuN|c3PDJizszN MULTRW5ITVJ?
BV-173 M3jtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOycVhKSzVyPUCuN|k{OiEQvF2= NHTG[WhUSU6JRWK=
K5 NWHWdYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TYd2lEPTB;MD60NlEzPyEQvF2= NUTDU4doW0GQR1XS
MEG-01 M{G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK5WIg4UUN3ME2wMlQzOzZzIN88US=> MlSyV2FPT0WU
MFM-223 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILKUmhKSzVyPUCuOFQ4PzZizszN MVHTRW5ITVJ?
BE-13 NID5eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNUGwNFgh|ryP MYDTRW5ITVJ?
NEC8 NYi1W2ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXFNmZKSzVyPUCuO|IyOTNizszN NYDwSFREW0GQR1XS
SW756 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuw[mR6UUN3ME2wMlk6QDR4IN88US=> MUXTRW5ITVJ?
A2780 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzOXFjUUN3ME2xMlAyOTR4IN88US=> MUjTRW5ITVJ?
NB14 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwMEG4NFEh|ryP MnroV2FPT0WU
H4 NWnQe|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXZUVVKSzVyPUGuNFY1OjJizszN MX3TRW5ITVJ?
SK-OV-3 M{nUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\MSGlEPTB;MT6wOlY{OyEQvF2= M13OOXNCVkeHUh?=
AN3-CA M4j0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFywR5dKSzVyPUGuNFg{QDlizszN MWfTRW5ITVJ?
A427 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Czd2lEPTB;MT6xNFM5OSEQvF2= MX7TRW5ITVJ?
ES7 NXnqT3ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ex[mlEPTB;MT6xNVM{PCEQvF2= MYrTRW5ITVJ?
AGS MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP5TWM2OD1zLkGxN|k2KM7:TR?= NYnXd|kyW0GQR1XS
G-402 NXT1U2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363XmlEPTB;MT6xOFY6PCEQvF2= MUTTRW5ITVJ?
ES5 M4Tk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXJTWM2OD1zLkG3NlQ5KM7:TR?= M1q1fnNCVkeHUh?=
DEL NWD4OW5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj3TWM2OD1zLkK1OFU4KM7:TR?= MomxV2FPT0WU
NB10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHGTWM2OD1zLkOyOVU4KM7:TR?= MnHuV2FPT0WU
NCI-H1581 M4T4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3GTWM2OD1zLkO5NFQzKM7:TR?= NGfFOFhUSU6JRWK=
D-566MG MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXRdGlrUUN3ME2xMlQxPjh|IN88US=> NITBc4tUSU6JRWK=
LXF-289 NVi2cVVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHCTWM2OD1zLkSzPVk3KM7:TR?= MVHTRW5ITVJ?
BT-549 M2e1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHZU3JKSzVyPUGuOVY6ODlizszN NIHsRY5USU6JRWK=
NKM-1 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzTPG5XUUN3ME2xMlYxPTV4IN88US=> M3LQN3NCVkeHUh?=
SW780 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH3TWM2OD1zLk[1NVU5KM7:TR?= NXe4[YNyW0GQR1XS
NCI-H292 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwNk[zPFMh|ryP M{PVdHNCVkeHUh?=
HMV-II NEn2eWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorSTWM2OD1zLkewOFg5KM7:TR?= MkHLV2FPT0WU
ALL-PO NFfGeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ZeWlEPTB;MT64NFAyPSEQvF2= M2W5fnNCVkeHUh?=
UACC-257 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrqSGlKSzVyPUGuPFIyPjNizszN NV76boV3W0GQR1XS
PA-1 M{HiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hVIpXUUN3ME2xMlgzPzJ3IN88US=> MoL1V2FPT0WU
HD-MY-Z M1fudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqwTWM2OD1zLki2NlgyKM7:TR?= NUHkN49EW0GQR1XS
HSC-4 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DNUGlEPTB;MT65N|g{QSEQvF2= MW\TRW5ITVJ?
GCT MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwMEC5NVYh|ryP Mn7DV2FPT0WU
RT-112 NG\NWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HScWlEPTB;Mj6xN|QzPCEQvF2= NVP2TVV4W0GQR1XS
A172 NXnOb5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwMUO2NFYh|ryP NHfTNHVUSU6JRWK=
HCE-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H0O2lEPTB;Mj6yNFU6QCEQvF2= M3rsU3NCVkeHUh?=
YH-13 NHTPdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7QSVNkUUN3ME2yMlIyPjdzIN88US=> MnfFV2FPT0WU
DK-MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfVNGNKSzVyPUKuNlM5OzRizszN MXjTRW5ITVJ?
ACN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KxNGlEPTB;Mj6yN|g4PSEQvF2= M1XFZnNCVkeHUh?=
VA-ES-BJ NXq4boRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXPTWM2OD1{LkK0PVU4KM7:TR?= NGTGSZpUSU6JRWK=
L-363 NFHINpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIroZolKSzVyPUKuNlgxPjFizszN M1PNVHNCVkeHUh?=
HuH-7 NVLyc2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnMTZJTUUN3ME2yMlQzOTZ3IN88US=> MlOzV2FPT0WU
A4-Fuk MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOzUYlKSzVyPUKuOFcyPjhizszN M3;4THNCVkeHUh?=
T-24 M2PjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3qTWM2OD1{LkS4NFM4KM7:TR?= M1zRRXNCVkeHUh?=
GOTO M{\3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH1[|U3UUN3ME2yMlU{ODF|IN88US=> NFPqVGFUSU6JRWK=
MV-4-11 M2K0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJwNUmxOlkh|ryP Ml20V2FPT0WU
DMS-114 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwNk[zOFUh|ryP NVzMbYRtW0GQR1XS
MHH-NB-11 M{HneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTjUpA4UUN3ME2yMlcxOjl7IN88US=> NY[0SJNzW0GQR1XS
CHP-212 NH\FeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwOEKwPVEh|ryP NGX6cItUSU6JRWK=
DMS-273 NFrsfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrYcpJKSzVyPUKuPVAzODdizszN NGDieopUSU6JRWK=
SF295 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrqRotKSzVyPUOuNFI2QTdizszN NV3rO5BiW0GQR1XS
NCI-H1563 M4\0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwMUWwNFUh|ryP NX7wSGtDW0GQR1XS
NCI-H446 M4PJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMkK4NFUh|ryP MV;TRW5ITVJ?
HCC1806 NXq1dJRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\KTWM2OD1|LkK3OlU4KM7:TR?= M2HF[3NCVkeHUh?=
SF126 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLBTWM2OD1|LkOwNFE4KM7:TR?= MYTTRW5ITVJ?
SW982 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwM{O4O|Uh|ryP Ml3uV2FPT0WU
ES8 NUXJenNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHoXppKSzVyPUOuN|Q6QTlizszN M4C2dHNCVkeHUh?=
SCC-4 NFvXUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T0TWlEPTB;Mz61NFM6PiEQvF2= NV6zeFhRW0GQR1XS
RPMI-8226 NEXqbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDQe3pKSzVyPUOuOlI3OTZizszN M3XqUnNCVkeHUh?=
EW-11 NFj1dGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjIRoNKSzVyPUOuOlMxOjJizszN MVnTRW5ITVJ?
COR-L105 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP4OWFKSzVyPUOuOlM{OzRizszN NXnWVGZFW0GQR1XS
ES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwOEOwPVQh|ryP M33HRnNCVkeHUh?=
KMOE-2 M{K1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nWUWlEPTB;Mz65NVgxQCEQvF2= NIr1blRUSU6JRWK=
ABC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m5d2lEPTB;Mz65N|kyOSEQvF2= Mo\OV2FPT0WU
NCI-H526 M2X2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fON2lEPTB;Mz65PVEzPiEQvF2= MorQV2FPT0WU
HCC1395 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPoTWM2OD1|Lkm5OFg1KM7:TR?= NULtfWV{W0GQR1XS
DU-145 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;HUFlKSzVyPUSuNVI5OjVizszN NHrNUpZUSU6JRWK=
JEG-3 NXnk[lJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwMUW5NVYh|ryP NXvF[nQ1W0GQR1XS
HCC1187 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHaNWNKSzVyPUSuNlE2QTdizszN M2naUnNCVkeHUh?=
LC-2-ad NUnrdWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3JTHBKSzVyPUSuNlIyPzdizszN NX\UdFJyW0GQR1XS
ONS-76 NHLIeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG3TWM2OD12LkK0NVkzKM7:TR?= MV7TRW5ITVJ?
CAL-27 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\CTWM2OD12LkK0N|Q1KM7:TR?= MoPjV2FPT0WU
8-MG-BA MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33IZmlEPTB;ND6yOlY2QCEQvF2= NWXPXGw6W0GQR1XS
HGC-27 NXHRTnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTRwMkm2OkDPxE1? MUPTRW5ITVJ?
Hs-578-T MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwM{G0Olgh|ryP MmToV2FPT0WU
EW-1 NEW3cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0TWM2OD12LkWzNFE1KM7:TR?= MXXTRW5ITVJ?
SW1573 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRwNUWxOlMh|ryP MV\TRW5ITVJ?
SNU-423 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrXTWM2OD12Lk[wO|kh|ryP NW\aNVhkW0GQR1XS
HOS NXKyfpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRwNkm3O{DPxE1? NFzBXI9USU6JRWK=
LB1047-RCC M1jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C4bmlEPTB;ND64NVQyQCEQvF2= MnfCV2FPT0WU
ChaGo-K-1 NGqzXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe1R2F5UUN3ME20Mlg6ODR6IN88US=> MoL1V2FPT0WU
A3-KAW M2LJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjLfYVKSzVyPUSuPVc{PTJizszN M2iwZXNCVkeHUh?=
CAS-1 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHz[257UUN3ME20Mlk6QTB6IN88US=> MljwV2FPT0WU
NBsusSR MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTVwMEO1NVQh|ryP NWDHU|g{W0GQR1XS
KM12 M3jxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nlcmlEPTB;NT6yPVgzPyEQvF2= NXqzbYd3W0GQR1XS
NCI-H1155 NU\vXHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfCSHJyUUN3ME21MlM5OTh3IN88US=> MXTTRW5ITVJ?
EFM-19 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17iTGlEPTB;NT60NVc{PyEQvF2= MYHTRW5ITVJ?
D-392MG NVPkN5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILu[4VKSzVyPUWuOVc5PDlizszN MWXTRW5ITVJ?
JVM-3 NXm3[Hd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jON2lEPTB;NT63NlMzPSEQvF2= NF;xeYZUSU6JRWK=
EW-16 M33WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;LXWlEPTB;NT63OVU5OyEQvF2= NWDvPYM{W0GQR1XS
KARPAS-45 NF73PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HNc2lEPTB;NT64OFMzPSEQvF2= M4HEZnNCVkeHUh?=
NCI-H28 NIL4V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljKTWM2OD13Lki3PVE5KM7:TR?= MWDTRW5ITVJ?
COLO-829 NVm0XWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXaTWM2OD13LkmxOVA1KM7:TR?= M{LacHNCVkeHUh?=
KM-H2 NX\jfW01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TZcmlEPTB;NT65NlM6PSEQvF2= NVi1b2pzW0GQR1XS
NCI-H82 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO2ZmJHUUN3ME21MlkzPzdzIN88US=> M1W0SHNCVkeHUh?=
OAW-42 NGnve2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXwOZBKSzVyPUWuPVg5OjFizszN MU\TRW5ITVJ?
A704 M{fmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTZwMUC1O|Qh|ryP NHO1VYtUSU6JRWK=
NCI-H1048 NXn5RlBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXVR4pKSzVyPU[uNVA2QTlizszN NHjU[lJUSU6JRWK=
LOXIMVI Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;I[|B7UUN3ME22MlEyOjR6IN88US=> Mk\hV2FPT0WU
MKN45 M2DEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTod2JyUUN3ME22MlI3ODF4IN88US=> NFL6RWhUSU6JRWK=
D-502MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P5cWlEPTB;Nj6yPFg2PyEQvF2= Mn;BV2FPT0WU
HUTU-80 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXnTWM2OD14LkSxOlg5KM7:TR?= NVS5bXpSW0GQR1XS
S-117 NFz3PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm2TWM2OD14LkWwNlY4KM7:TR?= NHjXW41USU6JRWK=
HCC1569 NFK5d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n5T2lEPTB;Nj61N|c{PyEQvF2= MXTTRW5ITVJ?
J-RT3-T3-5 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZwNUS1O|Ih|ryP M2\lPHNCVkeHUh?=
OC-314 NFLJdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnkcXpKSzVyPU[uPVEyPTlizszN MYjTRW5ITVJ?
SNU-449 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrrTWM2OD15LkCxNFczKM7:TR?= NWjYUY9ZW0GQR1XS
NCI-H720 NUPVO4x1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrhTWM2OD15LkG5N|Q2KM7:TR?= MXjTRW5ITVJ?
KP-N-YS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjSW4dKSzVyPUeuNlA4OiEQvF2= NYL2bYVpW0GQR1XS
IGROV-1 NGDoUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\1dHZwUUN3ME23MlMzOzh4IN88US=> NFrmTIJUSU6JRWK=
SK-PN-DW NX;1OZFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS1XlhFUUN3ME23MlQ5OTVizszN NF2xcnhUSU6JRWK=
HCC1419 NWrXb5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmx[WtKSzVyPUeuOVMh|ryP NYr3emVPW0GQR1XS
HAL-01 M3zKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTac4JKSzVyPUeuOlA3PDRizszN NVLiO2QzW0GQR1XS
HCC2998 M1zpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LFb2lEPTB;Nz62NFc1OyEQvF2= M4L0WnNCVkeHUh?=
SK-N-FI NGPXflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUexblRpUUN3ME23MlY{ODN|IN88US=> MoixV2FPT0WU
GI-ME-N NVvOUnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD15Lk[0PVM1KM7:TR?= MWrTRW5ITVJ?
SW1088 NYjtWlBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ruUWlEPTB;Nz62OVgzPiEQvF2= NUfyXplqW0GQR1XS
IA-LM M{[wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfNdJlKSzVyPUeuOlg3OTNizszN NGjvbJVUSU6JRWK=
SK-NEP-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jwOmlEPTB;Nz62PVYyKM7:TR?= M3rkPXNCVkeHUh?=
MDA-MB-415 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr1V2RoUUN3ME23Mlg6OTh4IN88US=> NYfIVW1qW0GQR1XS
COLO-800 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3STWM2OD15Lkm0OFkzKM7:TR?= M320WHNCVkeHUh?=
NCI-H2228 NWC5b4FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nWOGlEPTB;OD6xOVc5OyEQvF2= MlfCV2FPT0WU
D-423MG NYLL[FVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX4cFdxUUN3ME24MlIyPzJizszN NHjDZnBUSU6JRWK=
TE-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fyPGlEPTB;OD60OFMyPiEQvF2= NXnPS5pYW0GQR1XS
NOS-1 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy3[pVKSzVyPUiuOVE2OzRizszN M3;uUHNCVkeHUh?=
8505C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljiTWM2OD16Lk[0PFI1KM7:TR?= M2D4W3NCVkeHUh?=
HEC-1 NYDZ[4xST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnlUWZTUUN3ME24Mlc5PDN7IN88US=> MmDEV2FPT0WU
TE-11 NF\udoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRThwOUm1OVEh|ryP NEjxbZRUSU6JRWK=
CTB-1 M3vvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq0TWM2OD17LkCxOFM{KM7:TR?= MXTTRW5ITVJ?
TGBC11TKB M2DYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTlwMEKyOFEh|ryP MYfTRW5ITVJ?
NB17 NXno[GtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTlwMUi4O{DPxE1? NWjFe2REW0GQR1XS
Becker M{\BNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7kTWM2OD17LkSxPVQ1KM7:TR?= Mn\sV2FPT0WU
SN12C MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PaWGlEPTB;OT60OVI{PCEQvF2= M1zXUnNCVkeHUh?=
COLO-320-HSR MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwNkCyN|ch|ryP M3;WcXNCVkeHUh?=
D-283MED M1LmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DOPWlEPTB;OT62N|A4OiEQvF2= NYPlcnZMW0GQR1XS
D-263MG MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtd3ZyUUN3ME25Mlg{Ozh2IN88US=> NGT5bIxUSU6JRWK=
MEL-JUSO M4rNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj4eotKSzVyPUmuPVAyOjdizszN NWLXdWV3W0GQR1XS
T98G NFfXeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXWO4JEUUN3ME25MlkxOjB|IN88US=> MVHTRW5ITVJ?
HLE M4nhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwOUC5NFkh|ryP M1\mPXNCVkeHUh?=
Ca9-22 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7CTWM2OD1zMD6wOlY2KM7:TR?= NVSyRW5DW0GQR1XS
OS-RC-2 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrQOGhXUUN3ME2xNE4yODR3IN88US=> MVHTRW5ITVJ?
T47D MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3wcVF3UUN3ME2xNE4yPTVizszN M2C5[3NCVkeHUh?=
GI-1 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHMTWM2OD1zMD6zOVM{KM7:TR?= NGO4SHFUSU6JRWK=
NUGC-3 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPmTWM2OD1zMD60OFAzKM7:TR?= NH\4SYpUSU6JRWK=
MDA-MB-361 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmxTWM2OD1zMD60OFMzKM7:TR?= NXK0b3RiW0GQR1XS
SCC-15 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD1zMD60O|E5KM7:TR?= M{H5c3NCVkeHUh?=
KS-1 NYP5PWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorLTWM2OD1zMD62N|AyKM7:TR?= MULTRW5ITVJ?
CAL-12T M2nxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\G[2lEPTB;MUCuOlM3OSEQvF2= M2n2N3NCVkeHUh?=
OVCAR-4 M1Ludmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13OS2lEPTB;MUCuO|A3QCEQvF2= M2nwTXNCVkeHUh?=
HuP-T4 NHnPb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPlTWM2OD1zMT6wN|I5KM7:TR?= MmnPV2FPT0WU
NCI-H358 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zt[GlEPTB;MUGuNlY2PyEQvF2= MW\TRW5ITVJ?
HO-1-N-1 M3XSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfLb5NsUUN3ME2xNU4{Ozl6IN88US=> MmLTV2FPT0WU
NH-12 NEm4TW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr3cY56UUN3ME2xNU42Ozd6IN88US=> NXHycWg6W0GQR1XS
MOLT-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rJZ2lEPTB;MUGuOVk5PSEQvF2= MorZV2FPT0WU
K-562 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnIfmtKSzVyPUGxMlczPDhizszN MkLaV2FPT0WU
ES6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHrNZlKSzVyPUGxMlg2QDFizszN M{HmSXNCVkeHUh?=
RO82-W-1 M17pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFzLkmwOlQh|ryP NXTUe2loW0GQR1XS
Ramos-2G6-4C10 NE\6[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fGSWlEPTB;MUGuPVMzKM7:TR?= NVTwS3BCW0GQR1XS
23132-87 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXWdm9TUUN3ME2xNk4xQDJzIN88US=> MWrTRW5ITVJ?
A549 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4SWJKSzVyPUGyMlMzQDVizszN M37RWnNCVkeHUh?=
NCI-H23 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSyTWM2OD1zMj61NFI3KM7:TR?= Mme5V2FPT0WU
H9 NX73T5pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDBT3ZKSzVyPUGyMlU2PzdizszN M2\KO3NCVkeHUh?=
LB771-HNC NXXkOFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV72OmpsUUN3ME2xNk44PjVizszN MnizV2FPT0WU
QIMR-WIL M{DKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTETWM2OD1zMj64NlU5KM7:TR?= NEXi[YlUSU6JRWK=
HSC-3 NUTZcIdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\5NW9KSzVyPUGyMlkzPzZizszN NVq4O4wyW0GQR1XS
PFSK-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fDVWlEPTB;MUKuPVUxPyEQvF2= MmLoV2FPT0WU
ETK-1 NHr1[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ybVZKSzVyPUGzMlA4PzlizszN MU\TRW5ITVJ?
SW1710 M2jMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3zdWFKSzVyPUGzMlM3PDFizszN MnvjV2FPT0WU
COLO-684 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF|LkS1OFEh|ryP NIPD[lZUSU6JRWK=
RPMI-7951 NEHUfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;1RWlEPTB;MUOuOVE{PiEQvF2= M{PZOXNCVkeHUh?=
A101D MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:0cplJUUN3ME2xN{42OzR7IN88US=> NUXD[3hyW0GQR1XS
KE-37 M1rLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrDXmtVUUN3ME2xN{42QDh5IN88US=> MX\TRW5ITVJ?
SiHa NFjKSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzDe4tKSzVyPUGzMlg{PDZizszN NV;GOY9RW0GQR1XS
NCI-H226 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e4[WlEPTB;MUOuPFgxQCEQvF2= NFe3SG5USU6JRWK=
DB MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP5TWM2OD1zMz65PVI5KM7:TR?= MnvrV2FPT0WU
HT-1197 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF2LkC4NFkh|ryP MWLTRW5ITVJ?
SBC-5 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD1UVdXUUN3ME2xOE4yOzZ{IN88US=> M3PWVHNCVkeHUh?=
VMRC-RCZ NWPtO5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrqTWM2OD1zND61O|c1KM7:TR?= M2TsbXNCVkeHUh?=
697 NYLVUIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHnTWM2OD1zND62Nlch|ryP NXn3[VFVW0GQR1XS
OMC-1 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nGSGlEPTB;MUSuO|g5QCEQvF2= NYHXe2ZoW0GQR1XS
SKG-IIIa Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTBTWM2OD1zND64NFAyKM7:TR?= NIDNXWFUSU6JRWK=
DOK NHHxS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF2Lkm5N|Mh|ryP MoP1V2FPT0WU
NCI-H2029 NVnjSYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XhdGlEPTB;MUWuN|YxOiEQvF2= Mo\4V2FPT0WU
NCI-H2009 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wTWM2OD1zNT61NFk2KM7:TR?= MVnTRW5ITVJ?
LK-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj4TWM2OD1zNT62OFQ6KM7:TR?= MVvTRW5ITVJ?
NCI-H661 NF;BPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Tt[2lEPTB;MUWuPVA4PSEQvF2= NV\PNnlsW0GQR1XS
GT3TKB M3TmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Loc2lEPTB;MU[uNFY4PiEQvF2= MlnlV2FPT0WU
GP5d MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1zNj6zOFIh|ryP M{XXSnNCVkeHUh?=
SK-MEL-2 M4fTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrZ2lEPTB;MU[uOFQ5PSEQvF2= MoDQV2FPT0WU
SK-UT-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnh[3VKSzVyPUG2MlU3PSEQvF2= MlzOV2FPT0WU
NB7 M{TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTCbWdTUUN3ME2xOk43QTdzIN88US=> NXTCeYt7W0GQR1XS
NCI-H460 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF4LkezNlYh|ryP NHKwS5ZUSU6JRWK=
8305C NFG4c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF4Lke4O|ch|ryP MonyV2FPT0WU
CaR-1 NVnqTHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PES2lEPTB;MU[uPFEyOSEQvF2= M1rjcnNCVkeHUh?=
D-247MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr1RpBKUUN3ME2xOk45PjJ3IN88US=> NGnqPWJUSU6JRWK=
LoVo Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF4Lkm0PFgh|ryP MXTTRW5ITVJ?
NCI-H2405 NUK4NWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG2TWM2OD1zNz6xPVA5KM7:TR?= M2fRTXNCVkeHUh?=
AU565 NILlUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF5LkKyOUDPxE1? NInPOWpUSU6JRWK=
OCI-AML2 M4rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF5LkWzNVch|ryP NFPnT4dUSU6JRWK=
22RV1 M3jDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDUTWM2OD1zNz61PFg1KM7:TR?= M4nqcXNCVkeHUh?=
HT-144 NHHnOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTGbFI6UUN3ME2xO{43PTl6IN88US=> MUHTRW5ITVJ?
HuO9 M3W5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wTWM2OD1zNz63NFMyKM7:TR?= MXXTRW5ITVJ?
Daoy NHjxNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH0V4JzUUN3ME2xO{44OTh2IN88US=> MmfYV2FPT0WU
SJRH30 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnmUmd4UUN3ME2xO{45PDh7IN88US=> M{XKdHNCVkeHUh?=
CHL-1 NVPVTng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVezPJZyUUN3ME2xO{46OjR7IN88US=> NX7vSY9UW0GQR1XS
J82 NGXLZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToTWM2OD1zNz65OlM2KM7:TR?= M4n1[3NCVkeHUh?=
COR-L23 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXnTWM2OD1zOD6wNFEyKM7:TR?= NE[zOHVUSU6JRWK=
SNU-C2B MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf6cJZkUUN3ME2xPE4zOjd4IN88US=> MmK2V2FPT0WU
NCI-H1770 NWfYdllLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF6LkS2NVUh|ryP NF\5XnZUSU6JRWK=
MHH-PREB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj5SZNKSzVyPUG4MlU3QTdizszN MmX4V2FPT0WU
ES3 M1m3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH2NlhKSzVyPUG4MlU5QDNizszN MUDTRW5ITVJ?
MDA-MB-231 NH25SHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF6Lk[1NFIh|ryP NEe3[HZUSU6JRWK=
MN-60 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF7LkC1PVIh|ryP MWHTRW5ITVJ?
EPLC-272H MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\LNWlEPTB;MUmuN|cxQCEQvF2= MXzTRW5ITVJ?
SW948 NXPkcndUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1c2I6UUN3ME2xPU4{QTN2IN88US=> MknRV2FPT0WU
MOLT-13 NVfNblVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fiTGlEPTB;MUmuOFU1PiEQvF2= NHnmbHhUSU6JRWK=
HL-60 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6TWM2OD1{MD6yNVQyKM7:TR?= NFfvUFlUSU6JRWK=
CP50-MEL-B M2SwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjQ[HVEUUN3ME2yNE41PzR6IN88US=> MXjTRW5ITVJ?
NTERA-S-cl-D1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHldZZKSzVyPUKwMlQ6PzhizszN NFj3N4tUSU6JRWK=
KINGS-1 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXzWJN7UUN3ME2yNE44QTZ5IN88US=> MVLTRW5ITVJ?
DOHH-2 NEnsWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJyLkmwOkDPxE1? M3i5eXNCVkeHUh?=
BB65-RCC NH7QOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJyLkmyPFUh|ryP M1jhbXNCVkeHUh?=
NB12 NUO0UohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Jc4NVUUN3ME2yNU4xOzl2IN88US=> NGLSWZJUSU6JRWK=
KY821 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jKemlEPTB;MkGuOVgzKM7:TR?= M17wTnNCVkeHUh?=
PSN1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\xVmlEPTB;MkGuOlQ2OyEQvF2= MkLQV2FPT0WU
EGI-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnKfmU4UUN3ME2yNU44PDV2IN88US=> NU\hd29lW0GQR1XS
CTV-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qyNmlEPTB;MkKuN|A{OSEQvF2= NH3DS2dUSU6JRWK=
TI-73 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfRcZlKSzVyPUKyMlM1QThizszN NGD5XWhUSU6JRWK=
LCLC-103H MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGntflVKSzVyPUKyMlQ4PTJizszN MnrsV2FPT0WU
D-542MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXYbGtKSzVyPUKyMlU2PThizszN NH:yVVNUSU6JRWK=
ATN-1 NHqzPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XpdmlEPTB;MkKuOlQ{QSEQvF2= NWnxN4trW0GQR1XS
SK-MEL-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ{LkizOlgh|ryP NYnKR3hrW0GQR1XS
HDLM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2VJBuUUN3ME2yN{4yPDd6IN88US=> NWnMRWpKW0GQR1XS
UM-UC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ|LkG5OFQh|ryP MVPTRW5ITVJ?
NCI-H1573 NXyzXXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfuU5ZpUUN3ME2yN{41PjhzIN88US=> M1HyVXNCVkeHUh?=
NCI-H520 NI\URndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ|LkS5OFgh|ryP M4HTPXNCVkeHUh?=
ESS-1 NFrlZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ|LkiwOVkh|ryP Mn7mV2FPT0WU
COR-L88 NGXRO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ|Lkm0O|Uh|ryP MkK5V2FPT0WU
TGBC24TKB MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ2LkCzNVIh|ryP NUfVNJZKW0GQR1XS
HCC1937 M2LhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjqc4V3UUN3ME2yOE4yKM7:TR?= M13lN3NCVkeHUh?=
RS4-11 M1rMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S0eWlEPTB;MkSuNVQzKM7:TR?= NGLqTYJUSU6JRWK=
HCC38 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjBTWM2OD1{ND6yN|k1KM7:TR?= MWjTRW5ITVJ?
RPMI-2650 NIP6S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ2Lk[xOlIh|ryP MkPHV2FPT0WU
P12-ICHIKAWA NWO2RZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTXRZNvUUN3ME2yOE43OjV6IN88US=> M2fqfnNCVkeHUh?=
YAPC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HMPGlEPTB;MkSuPFIyPCEQvF2= M2rKRXNCVkeHUh?=
NB13 NVHv[5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ3LkK2NVEh|ryP MnHwV2FPT0WU
SK-N-AS MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD1{NT64OVg1KM7:TR?= MY\TRW5ITVJ?
SK-N-DZ NYXI[IZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrOTWM2OD1{Nj6wOFkh|ryP MYHTRW5ITVJ?
LS-411N MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ4LkKwN|gh|ryP M2OyenNCVkeHUh?=
NCI-H810 NEi5[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD1{Nj6zNVEzKM7:TR?= NWHLUJY6W0GQR1XS
NCI-SNU-1 NGDiWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\FWJFnUUN3ME2yOk42PDV2IN88US=> NUCyT|ZQW0GQR1XS
HH M4DLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTwZlgzUUN3ME2yOk42PTJ7IN88US=> MmjFV2FPT0WU
U-2-OS NUXmSWVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ4LkezPFIh|ryP NVq2TJhxW0GQR1XS
SF539 NHjPcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ4LkiwNVgh|ryP MnHyV2FPT0WU
NCI-H2052 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zMSmlEPTB;MkeuNFg3KM7:TR?= NILaRppUSU6JRWK=
A673 M162Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H6eGlEPTB;MkeuNlExOiEQvF2= NV\iTIRTW0GQR1XS
WM-115 M4fUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ5Lke3Olch|ryP NW[0NpBrW0GQR1XS
SW48 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXS[pRKSzVyPUK3MlgxODVizszN NH:4eGJUSU6JRWK=
NOMO-1 M4nJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnhWWdKSzVyPUK3Mlg2OzJizszN M1PjUXNCVkeHUh?=
PC-3 NEn4ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ5Lki5OFEh|ryP NHnVTJNUSU6JRWK=
UMC-11 NIHEUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ5LkmzOFMh|ryP NXu4WYhDW0GQR1XS
U-118-MG MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfMUI5KSzVyPUK4MlAyOjNizszN NH\OZXVUSU6JRWK=
NCI-H2452 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XYeGlEPTB;MkiuNFgzOiEQvF2= M2XNWnNCVkeHUh?=
CAMA-1 NHf3bGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iyU2lEPTB;MkiuPFU3PCEQvF2= Mlr4V2FPT0WU
MC-IXC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ7LkKzOlYh|ryP NFXNR4dUSU6JRWK=
ES4 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;qSGlEPTB;MkmuN|E4OiEQvF2= NWPqNWc2W0GQR1XS
BHT-101 NF3rVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPHTWM2OD1{OT6zNlEh|ryP NIrYXFhUSU6JRWK=
KP-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvRTWM2OD1{OT61NVYh|ryP M17ibHNCVkeHUh?=
CAL-54 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDUTWM2OD1{OT61OFQ2KM7:TR?= MoLCV2FPT0WU
5637 NWLSTFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe5O3FKSzVyPUK5MlY1OjFizszN NHrMXFJUSU6JRWK=
MOLT-16 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfYflNjUUN3ME2yPU44OjZ7IN88US=> Mn3pV2FPT0WU
Ca-Ski MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ7Lkm0OkDPxE1? NEnXRlBUSU6JRWK=
AsPC-1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PwSWlEPTB;M{CuNFIyOiEQvF2= M{GyS3NCVkeHUh?=
MSTO-211H Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;DTWM2OD1|MD6xOUDPxE1? M1O2[HNCVkeHUh?=
L-428 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f3bmlEPTB;M{CuOFA2KM7:TR?= NH65S2NUSU6JRWK=
SW1463 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPtTWpKSzVyPUOwMlU{QDNizszN NUfIZoUzW0GQR1XS
NCI-H1648 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNyLkW1O|Qh|ryP NEDBemJUSU6JRWK=
CAKI-1 NGHpVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOx[25KSzVyPUOwMlc4ODJizszN NWn5NpBXW0GQR1XS
YKG-1 NW\NSIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD1|MT6wNlY{KM7:TR?= M2r0bnNCVkeHUh?=
A2058 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LsOWlEPTB;M{GuNVE3PCEQvF2= MVnTRW5ITVJ?
A375 NYHvd4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLJdppKSzVyPUOxMlE3QTZizszN M3\lOXNCVkeHUh?=
SNB75 NH\6RmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mTWM2OD1|MT6yOFM2KM7:TR?= MVzTRW5ITVJ?
SK-HEP-1 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTtc|RKSzVyPUOxMlQzPzFizszN NIH4SmFUSU6JRWK=
ME-180 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHkTWM2OD1|MT62OVQzKM7:TR?= M1\2R3NCVkeHUh?=
NCI-H209 M2rMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1WWFDUUN3ME2zNU45OjR5IN88US=> NIrKWZlUSU6JRWK=
HC-1 NIG2[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLpNpF4UUN3ME2zNk4yPDR4IN88US=> MVfTRW5ITVJ?
LB373-MEL-D NX\LZ2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHFR3RKSzVyPUOyMlE6PzFizszN NHT1OXZUSU6JRWK=
SNU-387 NFX1fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M124VWlEPTB;M{KuN|E6OSEQvF2= MlG0V2FPT0WU
C32 M324RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q2T2lEPTB;M{KuN|M2OyEQvF2= NYrRNm1bW0GQR1XS
EW-13 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDwVVZKSzVyPUOyMlk1ODhizszN MXTTRW5ITVJ?
BFTC-905 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKyR2FKSzVyPUOzMlUyOzZizszN MXvTRW5ITVJ?
NCI-H1299 NWj2b2U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN|LkW2NlEh|ryP M1jvenNCVkeHUh?=
LU-135 M36z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW3TWM2OD1|Mz64NFEh|ryP Mmf5V2FPT0WU
NCI-H2122 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\kdFVVUUN3ME2zN{46QTZ4IN88US=> M3rHc3NCVkeHUh?=
SK-LMS-1 M2THeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBemlEPTB;M{SuOFExPyEQvF2= MmrTV2FPT0WU
LNCaP-Clone-FGC MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXa[WxKSzVyPUO0Mlg2OTVizszN M{\adnNCVkeHUh?=
NCI-H1092 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHCVW1lUUN3ME2zOU4zPzR5IN88US=> MoHoV2FPT0WU
MS-1 NX:2TFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPOOpNKSzVyPUO1MlMxOzhizszN MXHTRW5ITVJ?
KYSE-510 NFLTXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUiyVHBOUUN3ME2zOU42ODR{IN88US=> NV:2UlNjW0GQR1XS
NCI-H1793 NXLZVnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P5d2lEPTB;M{WuOlU1PSEQvF2= MWrTRW5ITVJ?
MIA-PaCa-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXrTWM2OD1|Nj6wOFk3KM7:TR?= NHz1V3BUSU6JRWK=
EW-22 NFLiO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN4LkSwO|Ih|ryP NI\BOYtUSU6JRWK=
IGR-1 NVTi[WR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN4LkixPFQh|ryP MnvWV2FPT0WU
HT-1080 M3\TNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTN5LkGyOUDPxE1? NHHZTXpUSU6JRWK=
M14 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HM[GlEPTB;M{euNVY1OiEQvF2= MkDTV2FPT0WU
786-0 NH;nemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTUTWM2OD1|Nz6yO|k1KM7:TR?= NFz1R4dUSU6JRWK=
MZ2-MEL NV;kUZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\rbYxyUUN3ME2zO{41PTBzIN88US=> MWDTRW5ITVJ?
NCI-H510A MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPt[pRKSzVyPUO3Mlk1OTJizszN M3e2RXNCVkeHUh?=
LAN-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnvc4RKSzVyPUO3Mlk2QDJizszN NEfLcGZUSU6JRWK=
SW620 NWXCW3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnUTWM2OD1|OD60PVc1KM7:TR?= NWXWOYJvW0GQR1XS
LB2241-RCC MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrO[|lLUUN3ME2zPU45OjB3IN88US=> MmTIV2FPT0WU
Detroit562 M2DZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRyLkGyOlgh|ryP MoXsV2FPT0WU
HN NGrReI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETLfZVKSzVyPUSwMlE4QDJizszN M1nVTHNCVkeHUh?=
HCT-15 M3fvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRyLkW5NFch|ryP NEDGe|lUSU6JRWK=
C2BBe1 NXO1Wo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi0SpBFUUN3ME20NE46OTV5IN88US=> NYT5ZWFiW0GQR1XS
A498 M3zRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPEPHBnUUN3ME20NU4{ODF3IN88US=> MXXTRW5ITVJ?
SK-MEL-24 NVTub4hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULYfFFqUUN3ME20NU41PzJ3IN88US=> NHLOVItUSU6JRWK=
OVCAR-5 NYK2T2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW5O|JKSzVyPUSxMlc4PjdizszN MVXTRW5ITVJ?
NCI-H1792 NVP6eWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRzLkm4NlEh|ryP MoHxV2FPT0WU
KOSC-2 M{HUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PxN2lEPTB;NEKuNlY6QSEQvF2= NIP6RmRUSU6JRWK=
Mo-T NInlSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\0RmlEPTB;NEKuPFk2QCEQvF2= MlXlV2FPT0WU
CFPAC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PmNGlEPTB;NEOuOFk1PCEQvF2= MYjTRW5ITVJ?
CAL-51 NYXpeZd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTR|LkW2NFUh|ryP MnnxV2FPT0WU
RH-18 NX3WbXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTR|LkiwOUDPxE1? M4\McHNCVkeHUh?=
EC-GI-10 M1HwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2frcWlEPTB;NEOuPFM1PyEQvF2= M4q3THNCVkeHUh?=
HSC-2 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR2LkCwPUDPxE1? MoHMV2FPT0WU
ML-2 NEntUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPITWM2OD12NT6yOlIyKM7:TR?= MVXTRW5ITVJ?
KNS-81-FD MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuyU4dIUUN3ME20OU44OzZ3IN88US=> MWPTRW5ITVJ?
NB6 M3TYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTUWs1UUN3ME20Ok4yOTFizszN NUG0RXVmW0GQR1XS
MCF7 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT4TWM2OD12Nj61OVM{KM7:TR?= NFzoN3lUSU6JRWK=
P30-OHK MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17SeGlEPTB;NE[uPFEyPyEQvF2= NGnH[GNUSU6JRWK=
BPH-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR4Lkm4NFUh|ryP NVnLXlF{W0GQR1XS
U251 NVjZRY9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR4Lkm5OEDPxE1? M3vCZnNCVkeHUh?=
MKN1 NGHMWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR5LkWxN|ch|ryP NUP1fGZZW0GQR1XS
A431 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzFeYRvUUN3ME20O{45OzN6IN88US=> NEXNbVdUSU6JRWK=
C8166 NFvRdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR7LkKwN|kh|ryP NWDLOWhkW0GQR1XS
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR7LkSwOlQh|ryP Mn3iV2FPT0WU
RMG-I MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorxTWM2OD12OT60OFQ1KM7:TR?= M3v0cXNCVkeHUh?=
CAL-72 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13vNWlEPTB;NEmuOlA4PSEQvF2= M3PsTHNCVkeHUh?=
SW962 Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLR[ZJQUUN3ME20PU46OzN{IN88US=> MX;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
0.5% CMC
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID